Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See why NVO stock is a buy.

This month, the Danish prime minister Mette Frederiksen takes up her presidency of the EU – and the timing could not be more ...

In 2004, 100 citizens lived in Ørestaden of Amager. Today, almost 26,000 live in Ørestad Parish alone, Politiken reports. Just over half of all residents in Ørestad Parish are internationals, almost ...

FC Copenhagen will start qualifying for the Champions League. The opponent will be the winner of the match between Differdange from Luxembourg and Drita from Kosovo. Sports director Sune Smith-Nielsen ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.

Spain is investigating Novo Nordisk over concerns it may be indirectly marketing its weight loss drugs. Euronews Health spoke to the country’s health secretary to find out more.

Novo Nordisk is partnering with WeightWatchers to offer consumers access to Wegovy after it abruptly ended its collaboration with Hims & Hers.

Novo Nordisk reported that it is advancing amycretin to a phase 3 study. Image source: Getty Images. The company is making the move after receiving feedback on earlier-stage testing.

Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss drug.